U.S. Point of Care Infectious Disease Testing Market Revenue to Attain USD 5.27 Bn by 2035

Published: 24 Mar 2026

Author: Precedence Research

Share:

U.S. Point of Care Infectious Disease Testing Market Revenue and Trends 2026 to 2035

The U.S. point of care infectious disease testing market size surpassed USD 2.23 billion in 2025 and is anticipated to reach around USD 5.27 billion by 2035. The market is expanding at a solid CAGR of 8.98% over the forecast period 2026 to 2035. The U.S. point-of-care infectious disease testing market is growing as the demand for faster diagnosis increases, helping doctors begin treatment at an earlier stage.

What are the Growth Factors that Drive the U.S. Point of Care Infectious Disease Testing Market?

The U.S. point-of-care infectious disease testing market is growing as the need for quick and easy diagnosis continues to rise, helping start treatment sooner and improve patient outcomes. Increasing cases of COVID-19, Influenza, and HIV/AIDS, along with better portable testing technologies, are supporting this growth. The shift toward convenient testing locations, along with government support and greater awareness about early detection, is also driving demand.

Segment Insights

• By disease, the influenza/flu segment has held a major revenue share of 24.42% in 2025. This strong growth is mainly due to the increasing number of infectious cases and the growing need for quick, easily accessible diagnostic solutions. Point-of-care tests have played an important role by providing fast results, helping in early detection and timely treatment. Since these tests can be used outside traditional laboratories, such as in clinics or even at home, they offer a high level of convenience for both patients and healthcare providers.
• By end-user, the hospitals segment dominated the market with the largest revenue share of 38.56% in 2025. The growth is driven by the increasing number of point-of-care diagnostic centers and the rising cases of communicable diseases. Hospitals play a key role as primary care settings, where patients are tested and treated for various infections such as Tuberculosis, making diagnosis and care more accessible and efficient.

Regional Insights

U.S. dominated the U.S. Point of Care Infectious Disease Testing Market with a major revenue share in 2025.

The U.S. healthcare industry is rapidly evolving, driven by a growing shift toward decentralized care and advancements in technologies such as miniaturized biosensors, multiplex testing panels, and CRISPR-based molecular testing. In May 2025, the Association for Diagnostics and Laboratory Medicine introduced updates to point-of-care regulatory requirements. Meanwhile, organizations like the Centers for Medicare & Medicaid Services and the College of American Pathologists continue to play a vital role in ensuring high standards of accuracy and quality in diagnostic testing.

U.S. Point of Care Infectious Disease Testing Market Coverage

Recent Developments

• On February 6, 2026, MedGenome announced the launch of its new blood test, MetaSeq. This advanced, culture-free metagenomic next-generation sequencing (mNGS) test can detect over 1,400 clinically relevant bacteria, fungi, parasites, and DNA viruses within about five days. Developed in collaboration with Noscendo’s DISQVER platform, MetaSeq works by analyzing microbial cell-free DNA (cfDNA), allowing it to identify pathogens even after antibiotic treatment. This makes it especially useful for improving diagnosis and treatment in critical cases such as sepsis, ICU patients, and individuals with weakened immune systems.

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/4461 

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344